Teleflex (NYSE:TFX – Get Free Report) and electroCore (NASDAQ:ECOR – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Volatility & Risk
Teleflex has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, electroCore has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and price targets for Teleflex and electroCore, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Teleflex | 1 | 5 | 5 | 1 | 2.50 |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
Teleflex currently has a consensus target price of $154.40, suggesting a potential upside of 3.13%. electroCore has a consensus target price of $18.00, suggesting a potential upside of 114.29%. Given electroCore’s higher possible upside, analysts plainly believe electroCore is more favorable than Teleflex.
Earnings & Valuation
This table compares Teleflex and electroCore”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Teleflex | $1.99 billion | 3.18 | -$905.64 million | ($23.29) | -6.43 |
| electroCore | $32.03 million | 2.37 | -$13.97 million | ($1.66) | -5.06 |
electroCore has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
95.6% of Teleflex shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 0.7% of Teleflex shares are held by company insiders. Comparatively, 7.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Teleflex and electroCore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Teleflex | -39.67% | 11.93% | 5.44% |
| electroCore | -39.96% | N/A | -81.35% |
Summary
Teleflex beats electroCore on 10 of the 15 factors compared between the two stocks.
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
